Frequently Asked Questions

Yes. At 8 weeks, participants assigned to heated yoga had significantly lower clinician-rated depression scores on the IDS-CR than participants assigned to waitlist control, with a large between-group effect size (Cohen d = 1.04, P < .001). In the repeated-measures model, depressive symptoms declined over time overall (b = −2.61, P < .001) and improved faster in the yoga group than in the waitlist group (time × arm effect: b = −3.09, P < .001).

Participants were prescribed at least 2 heated yoga classes per week for 8 weeks, but actual attendance was lower. The yoga group attended a mean of 10.3 ± 7.1 classes over 8 weeks, and only 36% attended 12 classes or more, yet depressive symptoms still improved compared with waitlist.

The study found only a nonsignificant trend between attending more classes and lower week 8 IDS-CR scores after controlling for baseline depression severity (b = −0.42, P = .09), and the binary attendance analysis was also nonsignificant (b = −2.58, P = .39). The authors concluded that benefit was observed despite attendance below the prescribed twice-weekly dose.

In the heated yoga arm, 59.3% of participants (n = 16) met response criteria and 44% (n = 12) achieved remission. In the waitlist arm, 6.3% (n = 2) were responders and 6.3% (n = 2) remitted.

Response was defined as a 50% or greater decrease in IDS-CR symptoms, and remission was defined as an IDS-C score below 14, as reported by the study.

In this trial, heated yoga was generally well tolerated, and no serious adverse events were reported. Among yoga participants, intervention-related adverse events included 3 mild events and 4 moderate events probably related to the intervention, plus 1 additional mild event related to the intervention.

Probably related events in the yoga arm included headache, back pain, knee pain, chills/nausea, and dizziness/vertigo. The authors described the intervention as feasible, acceptable, and safe in this study population.

Yes, the study did not find evidence that antidepressant use changed the effect of heated yoga on depressive symptoms over time. In sensitivity analyses, the time × arm × antidepressant use interaction was not significant (b = 0.99, P = .31).

This means the observed antidepressant effect of heated yoga in this trial was not significantly different based on whether participants were taking stable antidepressant medication.

The intervention was Bikram yoga, a standardized form of heated yoga practiced in a 105°F room. Each class lasted 90 minutes and included a sequenced series of 26 hatha yoga postures and 2 breathing exercises.

Participants were prescribed at least 2 classes per week for 8 weeks at 2 community heated yoga studios, and instructors were Original Hot Yoga certified.

This was a randomized controlled trial comparing 8 weeks of community-delivered heated yoga with a waitlist control. Eighty participants were randomized, and 65 participants were included in the analyses: 33 in the yoga group and 32 in the waitlist group.

The primary outcome was clinician-rated depressive symptom severity on the IDS-CR, measured by assessors who were blinded to treatment assignment at baseline and weeks 1, 3, 5, and 8. The study enrolled adults aged 18–60 years with moderate-to-severe depressive symptoms, defined by an IDS-CR score of 23 or higher.

Yes. Compared with waitlist, yoga participants showed significant improvement in the expected direction on several secondary measures, including trait and state anxiety on the STAI, depression severity on the HDRS-17, some SF-36 subscales, the Q-LES-Q, some EIFI subscales, and the Perceived Stress Scale.

The article reports that no secondary outcomes showed effects in the unexpected direction, although it does not provide all numerical values in the main text.

The main limitations were the lack of an active comparator, a sample that was primarily female (81.5%) and college educated (86.2%), and uncertainty about generalizability to patients with greater medical complexity. The authors also noted that they did not measure treatment resistance and do not know whether the findings generalize to severe treatment-resistant depression, mild depression, or depression with other medical or psychiatric comorbidities.

They also stated that it is unclear whether these results would hold up against an active comparison treatment.

Participants with higher baseline depression severity on the HDRS-17 were less likely to be included in the analyses and/or complete the end-of-treatment clinician assessment. The reported odds ratio was 0.88 per point higher baseline HDRS-17 score (95% CI, 0.78 to 0.99; P = .04).

For self-report end-of-treatment measures, yoga assignment, non-female gender, and higher baseline HDRS-17 scores were also associated with lower completion.